Comparing the current results to its competitors, C4 Therapeutics Inc reported Revenue increase in the 2 quarter 2026 by 2.75 % year on year. The revenue growth was below C4 Therapeutics Inc 's competitors' average revenue growth of 14.07 %, achieved in the same quarter.
C4 Therapeutics Inc 's Comment on Competition and Industry Peers
The company operates in a competitive environment that includes major pharmaceutical firms, specialty pharmaceutical companies, biotechnology organizations, academic institutions, governmental agencies, and both public and private research institutions. Competitors focus on protein degradation as well as the development of existing and new therapies. The industry is marked by numerous patents and frequent patent infringement claims. Several biotechnology companies are developing product candidates based on chimeric small molecules for targeted protein degradation, while large pharmaceutical companies and academic institutions have disclosed investments and research in this area. Competitors often possess greater financial resources and expertise in research and development, manufacturing, clinical trials, regulatory approvals, and marketing. Competition also extends to recruiting qualified personnel, establishing clinical trial sites, patient registration, and acquiring technologies.
September 20, 2025
In an era where multiple myeloma therapies are rapidly evolving, C4 Therapeutics Inc. has emerged front and center with their promising investigational drug, Cemsidomide. Presented at the International Myeloma Society Annual Meeting, Phase 1 clinical trial data has highlighted the potential of Cemsidomide to achieve remarkable efficacy in a heavily pre-treated relapsed/refractory multiple myeloma patient population. Key Findings from the Phase 1 Trial C4 Therapeutics demonstrated impressive results during the trial, revealing an overall response rate (ORR) of 50% at the highest dose level (100 mg) and a 40% ORR at the 75 mg dose level. These findings suggest that Cemsidomide may hold a best-in-class potentia...
November 5, 2024
Advancements in Cancer Treatment: C4 Therapeutics to Unveil Promising Data on Cemsidomide at ASH Annual Meeting The Stage is Set In the rapidly evolving landscape of cancer treatment, C4 Therapeutics (C4T) is poised to reveal groundbreaking data from their ongoing Phase 1/2 clinical trial of Cemsidomide, a pioneering drug candidate targeting multiple myeloma and non-Hodgkin’s lymphoma. This significant announcement will take place during the highly anticipated American Society of Hematology (ASH) Annual Meeting. To ensure a comprehensive understanding and engagement with the scientific community and stakeholders, C4T will host a detailed webcast presentation on Sunday, December 8, 2024, at 2 PM PT (5 PM E...
July 16, 2024
Innovating Oncology: C4 Therapeutics to Reveal Pioneering Data on Targeted Protein Degradation at ESMO Congress 2024 July 16, 2024 | Watertown, Mass. C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a trailblazing clinical-stage biopharmaceutical enterprise with a staunch commitment to the advancement of targeted protein degradation science, today heralded the forthcoming presentation of preliminary data from the monotherapy dose-escalation segment of its ongoing Phase 1/2 clinical trial of CFT1946. This innovative BiDAC degrader is designed to target mutant BRAF V600 solid tumors and will be showcased as a mini oral presentation at the prestigious European Society for Medical Oncology (ESMO) Congress 2024. E...
March 5, 2024
C4 Therapeutics Makes a Splash with Groundbreaking Preclinical Data on BiDAC DegradersAt the American Association for Cancer Research Annual Meeting 2024, C4 Therapeutics unveiled exciting new preclinical data showcasing the highly selective orally bioavailable BiDAC Degraders. This revolutionary technology has the potential to revolutionize cancer treatment by targeting specific proteins for degradation, promising better outcomes for patients.One of the most significant findings from C4 Therapeutics presentation was the demonstration of CFT1946 s promising activity as a single agent and in combination therapies. In preclinical models, CFT1946 exhibited remarkable efficacy in BRAF V600X Melanoma, Colorectal...
March 4, 2024
In a significant development that highlights the increasing importance of targeted protein degradation in oncology research, C4 Therapeutics (C4T) has announced a strategic discovery research collaboration with Merck KGaA, Darmstadt, Germany. This collaboration aims to combat critical oncogenic proteins while leveraging the strengths of two specific targeted protein degraders from C4T s internal discovery pipeline. This article explores the facts surrounding this partnership and assesses its potential impact on C4 Therapeutics.Facts:1. C4 Therapeutics announces a discovery research collaboration with Merck KGaA, Darmstadt, Germany.2. The collaboration focuses on combating critical oncogenic proteins, which a...
January 9, 2024
C4 Therapeutics, a frontrunner in the biopharmaceutical landscape, has recently revealed its strategic plan for 2024, outlining a keen focus on the development and progression of targeted protein degradation (TPD) medicines. C4 s dynamic shift towards this avant-garde field of biomedical science not only displays its innovative approach towards disease treatment but also predicts an impressive evolution for the larger pharmaceutical sector.Currently, the company is investing its resources and research prowess into Phase 1 Dose Escalation Trials of CFT7455 and CFT1946, novel compounds that may redefine the way we treat diseases in the not-too-distant future. The company has also reported that it expects multi...
C4 Therapeutics, Inc. (C4T), a clinical-stage biopharmaceutical company pioneering targeted protein degradation science, recently announced the presentation of new Phase 1 dose escalation data for relapsed/refractory multiple myeloma. The data was from the ongoing Phase 1/2 clinical trial of CFT7455, a MonoDAC degrader of IKZF1/3, and holds significant potential for the treatment of this challenging blood cancer. Additionally, the company reported a rise in revenue during the third quarter of 2023, showcasing its growth trajectory compared to competitors in the market. Overview of C4 Therapeutics Webcast: C4 Therapeutics will host a webcast on December 12, 2023, at 4:30 PM ET, focused on p...
Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.
Foghorn Therapeutics Inc is a biotechnology company focused on discovering and developing drugs that target the chromatin regulatory system to treat a range of diseases. The company utilizes its proprietary Gene Traffic Control platform to identify and validate new therapeutic targets related to the modulation of gene expression.
Curis Inc's business model revolves around the development and commercialization of innovative cancer therapies. They focus on discovering and advancing drug candidates targeting specific molecular pathways involved in cancer growth and survival. The company collaborates with pharmaceutical partners to conduct clinical trials and seek regulatory approval for their products.
Sources:
C4 Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on C4 Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
